Drug profile · INN
leflunomide
APO-LEFLUNOMIDE
leflunomide (APO-LEFLUNOMIDE) is a dihydroorotate dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — leflunomide
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 3
- Programs
- 10
- Data quality
- 0.89
Quick answer
leflunomide (APO-LEFLUNOMIDE) is a dihydroorotate dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydroorotate dehydrogenase inhibitor
Primary target: Dihydroorotate dehydrogenase (quinone), mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is leflunomide?
leflunomide (APO-LEFLUNOMIDE) is a dihydroorotate dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for leflunomide?
APO-LEFLUNOMIDE is a marketed brand name for leflunomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of leflunomide?
leflunomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.